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p<0.02), (b) prioritization of utilization of services of various 
health functionaries for treatment of and advice for children’s 
illnesses(r=+0.75, p<0.05), and (c) prioritization of households using 
water from different sources(r=+0.975, p<0.02). The method was also 
found to be more rapid (3.3 times) and less costly (6.3 times) compared 
to the traditional household survey method. (RCHA) for prioritization 
of community health problems in a rural community is validated. The 
information thus obtained can be utilized for purposes of health policy 
and program planning, monitoring and evaluation. This is especially 
relevant for micro planning of cancer screening programs in developing 
countries. Repeated use of questionnaires for monitoring disease con-
trol programs must be carefully considered. Further studies to conﬁrm 
and reconﬁrm the results of this study may be done before wider appli-
cation in tobacco control and cancer control of above methodology 
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Objective: Chemotherapy offers slight but signiﬁcant survival ad-
vantage compared to best supportive care.Best supportive care varies 
according to cultural differences. This study was planned to compare 
chemotherapy with best supportive care, set up in the management of 
inoperable lung cancer patients. 
Methods: Seventy-eight patients were included in the study, out of 
which 38 were in the chemotherapy group (standard chemotherapy) 
and 40 were in the supportive care group. Supportive care included 
psychological support from family, nutritional support, family support, 
palliative radiotherapy, pain relief and other symptomatic relief. They 
were followed up for a period of one year. The main outcome measure 
was survival from the date of diagnosis. 
Results: The median survival of patients in the chemotherapy group 
was signiﬁcantly better than that of patients in the supportive care 
group. In patients are non- small cell lung cancer, median survival was 
27.0 weeks in the chemotherapy group and 10.1 weeks the best sup-
portive care group. In patients with small cell lung cancer, this was 15.6 
weeks and 3.9 weeks respectively. 
The improvement in survival with chemotherapy was consistently 
present in subgroups based on stage and performance status. Although 
patients with better performance status had a higher survival beneﬁt 
with chemotherapy, even patients with poor performance status had 
signiﬁcant improvement in survival with chemotherapy. 
In patients with advanced lung cancer, chemotherapy results in a much 
better survival than best supportive care alone. 
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Background: Anemia is the most frequent hematological complication 
of cancer. Epoetin beta (E), an effective treatment of chemotherapy-
induced anemia in patients (pts) with solid tumors was administred 
three-times weekly. This study was to evaluate efﬁcacy and safety of E 
30 000 IU in pts with LC.
Methods: This study was an open-label, single-arm, multicenter trial 
between December 2003 and August 2005. Eligibility criteria were: 
informed consent, age >=18 yrs, WHO performance status 0/2, malig-
nant non-myeloid malignancies, on-going chemotherapy and anemia: 
hemoglobin (Hb) <12 g/dl. E 30 000 IU QW was administered SC for 
up to 16 weeks. Follow-up visits were scheduled after each chemother-
apy cycle. Primary endpoint was Hb response deﬁned as an Hb increase 
of >=2 g/dl (whatever the baseline Hb level) and/or an achievement of 
Hb level of >=12 g/dl or 13 g/dl with Hb levels <11 g/dl or >11 g/dl at 
baseline respectively). Time to Hb response, transfusion requirement, 
mood and cognitive functions were also assessed. Here, we focus spe-
ciﬁcally on the subgroup of pts with LC
Results: 102 pts with LC were enrolled. Characteristics of the popula-
tion are the following: 63% of pts were male and 28% >= 70 years old, 
69% of pts received 1st line chemotherapy (75% were platinum-based 
regimen). Median Hb level at baseline was 10.4 g/dl [7.9-12.3]. At end-
point, median Hb level increased to 13.2 g/dl [9.3-15.0]. Hb response 
rate (RR) was: 54% (IC95: 44-64%), 56.6% (IC95: 43.3-69.9%) in pts 
treated with platinum based regimen and 61.1% (IC95: 38.6-83.6%) 
in pts treated without platinum. E treatment was well tolerated. No 
difference according to age, number of lines of treatment and type of 
chemotherapy. Thromboembolic events related to treatment occurred in 
2.9% of pts. 
Conclusion: Epoetin beta 30 000 IU once weekly is effective and well 
tolerated in anemic pts with lung cancer treated with platinum based 
chemotherapy. Once weekly treatment offers a convenient therapy 
which will improve patient compliance.
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Background: quality of life is an important outcome in lung patient 
treated by second line of chemotherapy. Alopecia may be an important 
part of this quality of life but in fact very few data’s are available.
Objective: the aim of this study is to assess, in patients treated by 
chemotherapy, the impact of alopecia.
Methods: This prospective, single centre study, use a willingness to 
pay method. Advanced LC patients (50 patients planned) were asked 
ﬁrst to assess the impact of alopecia in second line chemotherapy set-
ting from an analogical visual scale (from 0: no impact to 10 major im-
pact); then they participated, in a face to face interview, at the presenta-
tion of a hypothetical scenario with 2 chemotherapies with the same 
efﬁcacy, the same pattern of administration (every 3 weeks, in day care 
hospital) and the same tolerability except for the risk of alopecia: 5% 
